18 April 2024   Medtech moved more than $1 billion in income from its US operations to a Caribbean island | New twist in long-running transfer pricing dispute between company and the IRS over ‘arm's-length’ royalty owed under intercompany licences.

Latest Features

Biotechnology
As artificial intelligence creates a complex legal landscape for healthcare and medtech, Janine Swarbrick of HSF explores two case studies that shed light on how to claim an AI invention.
Plant Varieties
Applicants face tough scrutiny for claims around the laws of nature, but details of new processes, steps or guidance can help patents pass the courts’ two-step test, says Michael Taylor of Harness IP.
Biotechnology
It is critical that the emerging field of personalised medicine receives appropriate patent protection, explain Joel Coles and Theo Cooper of Powell Gilbert.
Unified Patent Court
Well-resourced NPEs looking to play the injunction card are eyeing up the court—companies with European operations should prepare, say Tom Oliver and Jessica Rosethorn of Powell Gilbert.
Biotechnology
Agreeing to a dispute resolution mechanism in an international joint venture requires forward thinking, say Jens Petry and Tom Gassmann, Squire Patton Boggs.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Generics
While President Biden’s desire to reduce costs at the pharmacy counter is commendable, it is too blunt an instrument that would threaten innovation beyond the life sciences, argue former USPTO directors Andrei Iancu and David Kappos.
Big Pharma
Kerri-Ann Limbeek, trial lead for Ravgen, tells Sarah Speight that a compelling narrative was key to winning the case against their larger rival.
All features


More News

9 April 2024   Annual global sales of Pfizer and Astella blockbuster drug reach roughly $5 billion | Nonprofits argue the drug is sold at a price three to six times higher in the US than it’s priced in other similar high-income countries | Move to curb drug prices follows controversial march-in rights plan.
4 April 2024   The Federal Circuit upholds a ruling in favour of Microsoft against an Orlando tech company | Dispute concerned 3D medical imaging technology | Court affirms PTAB’s decision to invalidate most of the patent.
4 April 2024   Senior pharma attorney and LSPN Boston speaker delves into emerging tech and patent law, the importance of communication and awareness, and the challenge of enablement | Advice on effective management of IP portfolios in the life sciences sector.
2 April 2024   Teva and co-appellant Mylan gain second chance at launching generics of Invega Sustenna, owned by J&J subsidiary Janssen | US Court of Appeals vacates a lower court’s decision to grant validity to the drug’s last remaining patent.
2 April 2024   Former Biogen counsel brings expertise in patent litigation for startups- Fortune 500 biotech giants | Experience in gene sequencing, computational biology, diagnostic software, and biosimilars.
28 March 2024   Judge disagrees that barrier against generic drug makers should be longer | Pharma company argues that ‘window should be shut’ on copycat versions due to potential for irreparable harm.
28 March 2024   Roche patent attorney Matt Flinders shares his perspectives on the impact of emerging tech on patent law and strategy | Insights into the challenges companies are facing with emerging tech.
More news